2026 Q1 -tulosraportti
98 päivää sitten
‧28 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 t sittenMuch speaks for approval, here is additional useful information that supports that reasoning. FDA's orphan-PDUFA 2025 – how many were actually approved? Compilation of orphan drugs with PDUFA decisions in 2025 with controlled outcome against FDA approvals. Results: - Total number of orphan-PDUFA: 43 - Approved: 37 - Complete Response Letter (CRL): 6 Approval rate: - 37 out of 43 = 86.0 % The figure of 83.7 % (36/43) sometimes mentioned is based on one drug still having a delayed PDUFA decision when the compilation was first made. That drug was: - Sebetralstat (Ekterly) – KalVista Pharmaceuticals The FDA extended the review because supplementary information had been submitted late. It was not a Complete Response Letter (CRL) and not a rejection. Subsequently, the drug was approved by the FDA on July 3, 2025. This means that the final result for 2025 was: - 37 approved - 6 CRL - 0 remaining postponed decisions Conclusion: The historical approval rate for orphan drugs with PDUFA decisions in 2025 was thus 86.0 %. Sources: - CheckRare – 2025 Orphan Drugs: PDUFA Dates and FDA Approvals (compilation of all orphan-PDUFA during the year). - FDA Orphan Drug Database – confirms that sebetralstat (Ekterly) was approved on July 3, 2025.- ·6 t sittenIs this when the speculative run-up starts before pdufa and we truly break out, towards 8-10kr before? Go egetis what strength with good volume lately
·1 päivä sittenOk, I'm on board here. It looks like a case with a high chance of success for the main product, and then with an accompanying lottery ticket. Based on what I've read, I assess that there is a solid discount to be had by buying now, rather than waiting until after September 28. I have bought a reasonable portion, and will probably buy a bit more in September if the price hasn't taken off by then. I think that a 25-50% increase must be achievable in the not too distant future.- ·1.8. · MuokattuPricing in Germany is out Approx. 113,000 SEK for 60 tablets is not bad according to me. Approx. 30% discount, which is reasonable and according to expectations, right. I read that 15% discount is mandatory by a new law so 15% above minimum is strong. A pack of 60 Emcitate (350 micrograms) tablets lasts on average between 20 and 60 days at a stable maintenance dose. The absolute most common is that it lasts for exactly 30 or 60 days depending on the patient's age and weight. Also sets the standard in the EU going forward. Weight is crucial for how many tablets it will be. But if one calculates 60tablets per month, it will probably be 12X10348=124 176 euro/patient/year1.35-1.5 million SEK/patient and year. Then one can think what it will be if the patient needs 120 tablets or more. Some average would be good to find but difficult. Can be approx. 1.35 to yes 2.7 million per year. Say average maybe 2 million.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
98 päivää sitten
‧28 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenMuch speaks for approval, here is additional useful information that supports that reasoning. FDA's orphan-PDUFA 2025 – how many were actually approved? Compilation of orphan drugs with PDUFA decisions in 2025 with controlled outcome against FDA approvals. Results: - Total number of orphan-PDUFA: 43 - Approved: 37 - Complete Response Letter (CRL): 6 Approval rate: - 37 out of 43 = 86.0 % The figure of 83.7 % (36/43) sometimes mentioned is based on one drug still having a delayed PDUFA decision when the compilation was first made. That drug was: - Sebetralstat (Ekterly) – KalVista Pharmaceuticals The FDA extended the review because supplementary information had been submitted late. It was not a Complete Response Letter (CRL) and not a rejection. Subsequently, the drug was approved by the FDA on July 3, 2025. This means that the final result for 2025 was: - 37 approved - 6 CRL - 0 remaining postponed decisions Conclusion: The historical approval rate for orphan drugs with PDUFA decisions in 2025 was thus 86.0 %. Sources: - CheckRare – 2025 Orphan Drugs: PDUFA Dates and FDA Approvals (compilation of all orphan-PDUFA during the year). - FDA Orphan Drug Database – confirms that sebetralstat (Ekterly) was approved on July 3, 2025.
- ·6 t sittenIs this when the speculative run-up starts before pdufa and we truly break out, towards 8-10kr before? Go egetis what strength with good volume lately
- ·1 päivä sittenOk, I'm on board here. It looks like a case with a high chance of success for the main product, and then with an accompanying lottery ticket. Based on what I've read, I assess that there is a solid discount to be had by buying now, rather than waiting until after September 28. I have bought a reasonable portion, and will probably buy a bit more in September if the price hasn't taken off by then. I think that a 25-50% increase must be achievable in the not too distant future.
- ·1.8. · MuokattuPricing in Germany is out Approx. 113,000 SEK for 60 tablets is not bad according to me. Approx. 30% discount, which is reasonable and according to expectations, right. I read that 15% discount is mandatory by a new law so 15% above minimum is strong. A pack of 60 Emcitate (350 micrograms) tablets lasts on average between 20 and 60 days at a stable maintenance dose. The absolute most common is that it lasts for exactly 30 or 60 days depending on the patient's age and weight. Also sets the standard in the EU going forward. Weight is crucial for how many tablets it will be. But if one calculates 60tablets per month, it will probably be 12X10348=124 176 euro/patient/year1.35-1.5 million SEK/patient and year. Then one can think what it will be if the patient needs 120 tablets or more. Some average would be good to find but difficult. Can be approx. 1.35 to yes 2.7 million per year. Say average maybe 2 million.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
2026 Q1 -tulosraportti
98 päivää sitten
‧28 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenMuch speaks for approval, here is additional useful information that supports that reasoning. FDA's orphan-PDUFA 2025 – how many were actually approved? Compilation of orphan drugs with PDUFA decisions in 2025 with controlled outcome against FDA approvals. Results: - Total number of orphan-PDUFA: 43 - Approved: 37 - Complete Response Letter (CRL): 6 Approval rate: - 37 out of 43 = 86.0 % The figure of 83.7 % (36/43) sometimes mentioned is based on one drug still having a delayed PDUFA decision when the compilation was first made. That drug was: - Sebetralstat (Ekterly) – KalVista Pharmaceuticals The FDA extended the review because supplementary information had been submitted late. It was not a Complete Response Letter (CRL) and not a rejection. Subsequently, the drug was approved by the FDA on July 3, 2025. This means that the final result for 2025 was: - 37 approved - 6 CRL - 0 remaining postponed decisions Conclusion: The historical approval rate for orphan drugs with PDUFA decisions in 2025 was thus 86.0 %. Sources: - CheckRare – 2025 Orphan Drugs: PDUFA Dates and FDA Approvals (compilation of all orphan-PDUFA during the year). - FDA Orphan Drug Database – confirms that sebetralstat (Ekterly) was approved on July 3, 2025.
- ·6 t sittenIs this when the speculative run-up starts before pdufa and we truly break out, towards 8-10kr before? Go egetis what strength with good volume lately
- ·1 päivä sittenOk, I'm on board here. It looks like a case with a high chance of success for the main product, and then with an accompanying lottery ticket. Based on what I've read, I assess that there is a solid discount to be had by buying now, rather than waiting until after September 28. I have bought a reasonable portion, and will probably buy a bit more in September if the price hasn't taken off by then. I think that a 25-50% increase must be achievable in the not too distant future.
- ·1.8. · MuokattuPricing in Germany is out Approx. 113,000 SEK for 60 tablets is not bad according to me. Approx. 30% discount, which is reasonable and according to expectations, right. I read that 15% discount is mandatory by a new law so 15% above minimum is strong. A pack of 60 Emcitate (350 micrograms) tablets lasts on average between 20 and 60 days at a stable maintenance dose. The absolute most common is that it lasts for exactly 30 or 60 days depending on the patient's age and weight. Also sets the standard in the EU going forward. Weight is crucial for how many tablets it will be. But if one calculates 60tablets per month, it will probably be 12X10348=124 176 euro/patient/year1.35-1.5 million SEK/patient and year. Then one can think what it will be if the patient needs 120 tablets or more. Some average would be good to find but difficult. Can be approx. 1.35 to yes 2.7 million per year. Say average maybe 2 million.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt